Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00033072
Verified November 2003 by National Institute on Drug Abuse (NIDA). Recruitment status was: Active, not recruiting
The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.
Condition or disease
To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
Be able to verbalize understanding of consent form; provide written informed consent